AMERI Hlds

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company was founded on February 28, 1994 and is headquartered in Naples, FL.

Ameri Holdings

NAPLES, Fla., Dec. 31, 2020 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), formerly AMERI Holdings, Inc. (NASDAQ: AMRH), a patient-centric biotechnology company endeavoring to enhance the lives of those who are adversely affected by the side effects...

Ameri Holdings Completes Spin-Off and Tender Offer, Changes Name to Enveric Biosciences and Begins Trading on the Nasdaq Under the Symbol "ENVB"

ATLANTA, Dec. 30, 2020 /PRNewswire/ -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri", the "Company"), announced a 1-for-4 reverse split of its common stock, effective as of 4:02 pm Eastern Time, December 30, 2020 (the "Reverse Stock Split"). As previously announced, at the special meeting...

AMERI Holdings Announces 1-for-4 Reverse Stock Split

ATLANTA, Dec. 29, 2020 /PRNewswire/ -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri", the "Company"), announced the voting results of the Special Meeting of stockholders that was held today. Based on the report from the Inspector of Elections, Ameri obtained sufficient votes for each...

AMERI Holdings' Stockholders Approve All Proposals To Complete Tender Offer For Jay Pharma Shares

ATLANTA, Dec. 23, 2020 /PRNewswire/ -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri", the "Company"), announced the adjournment of the Special Meeting of Shareholders that was scheduled to be held today to December 29, 2020 at 9:00 am EST. Valid proxies that have already been submitted...

AMERI Holdings Adjourns Special Stockholder Meeting To December 29th

ATLANTA, Oct. 23, 2020 /PRNewswire/ -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri", the "Company"), announced that it has filed an Amended Registration Statement on Form S-4 ("Amended S-4") with the Securities and Exchange Commission ("SEC"), which includes a preliminary proxy...

AMERI Holdings Files Amended Registration Statement On Form S-4

ATLANTA, July 29, 2020 /PRNewswire/ -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri"), announced that its proposed amalgamation partner Jay Pharma Inc.

Jay Pharma to File IND Applications to FDA for a clinical study of proprietary formulations in Radiodermatitis and a combination Therapy in Glioblastoma

AMERI Holdings, Inc. (“Ameri” or the “Company”), announced that the company is continuing to work through the regulatory review process towards finalizing the proposed amalgamation transaction with Jay Pharma, Inc. (“Jay Pharma”), a Canadian company dedicated to developing innovative, evidence-based cannabinoid products and combination therapies to address unmet needs in cancer care (the “Amalgamation”).

AMERI Holdings Provides Update On Pending Transaction With Jay Pharma Inc

ATLANTA, June 3, 2020 /PRNewswire/ -- AMERI Holdings, Inc. (NASDAQ: AMRH) (the "Company"), today announced that it has entered into a securities purchase agreement with institutional investors to purchase approximately $1.725 million of its common shares in a registered direct offering...

AMERI Holdings Announces Pricing Of $1.725 Million Registered Direct Offering Priced At-The-Market

Shares of AMERI Holdings Inc. AMRH, 218.66% were the biggest gainers and the second-most actively traded on major U.S. exchanges, after the company said that Jay Pharma Inc., the company it is merging into, has received a review board's approval to launch a phase I/II clinical trial of its cannabidiol (CBD) formulation of a treatment for a form of brain cancer (GBM).

AMERI's stock more than triples after merger partner expects to start human trials of CBD-based cancer treatment

ATLANTA and TORONTO, Jan.  13, 2020  (GLOBE NEWSWIRE) -- AMERI Holdings, Inc. (NASDAQ: AMRH) (“Ameri”) today announced it entered into an amalgamation agreement (the “Amalgamation Agreement”) with  Jay Pharma Inc.  (“Jay Pharma”), a Canadian company dedicated to developing innovative, evidence-based cannabinoid products and combination therapies to address unmet needs in cancer care, pursuant to which the shareholders of Jay Pharma will become the majority holders of Ameri’s outstanding stock by way of an amalgamation (the “Amalgamation”). In connection with the Amalgamation, Ameri will spin-off its existing IT services business to a private entity founded by Ameri management in partnership with Ameri’s current Series A Preferred Equity Holders (the “Spin-Off,” and collectively, with the Amalgamation, the “Transactions”). The Transactions are expected to close in the first half of 2020, subject to Ameri shareholder approval, approval of the Nasdaq Stock Market, and other customary closing conditions.

Ameri Holdings to Merge with Jay Pharma Inc., Evidence-Based Cannabinoid Medicine & Wellness Company Focused on Cancer

ATLANTA, Dec.  13, 2019  (GLOBE NEWSWIRE) -- AMERI Holdings, Inc. (NASDAQ: AMRH) (the “Company”), a specialized SAP® cloud, digital and enterprise solutions company, announced today that it had received written notice from the Nasdaq Stock Market (“Nasdaq”) Listing Qualifications Staff on December 10, 2019, indicating that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq considers the matter closed.

Ameri100 Regains Compliance With Nasdaq Listing Rule 5550(a)(2)

Company Selected As Greenfield Implementation Partner by Midstream Oil and Gas Customer Company Selected As Greenfield Implementation Partner by Midstream Oil and Gas Customer

Ameri100 Awarded Approximately $1 Million S/4HANA Implementation Contract

ATLANTA, Nov.  22, 2019  (GLOBE NEWSWIRE) -- AMERI Holdings, Inc. (Nasdaq: AMRH) (“Ameri100”), a specialized SAP® cloud, digital and enterprise solutions company, announced today that it will effect a reverse split of its common stock at a ratio of 1 for 25, effective Monday, November 25, 2019 (the “Effective Date”). The company’s common stock will begin trading on a split-adjusted basis when the markets open on the Effective Date under the existing trading symbol “AMRH.”

Ameri100 Announces 1-for-25 Reverse Stock Split to Regain Nasdaq Compliance

ATLANTA, Oct.  21, 2019  (GLOBE NEWSWIRE) -- AMERI Holdings, Inc. (NASDAQ: AMRH) (“Ameri100”), a specialized SAP® cloud, digital and enterprise solutions company, announced it is launching a series of joint webinars co-hosted with Google Cloud for current and prospective Ameri100 customers. The inaugural webinar will be held on Thursday, November 7, 2019. The webinars will be co-led by Ameri100 and Google Cloud SAP experts to educate customers and prospective customers about the significant benefits and differentiators of moving any size and type of SAP workload to Google Cloud Platform, especially as it relates to S/4HANA and C/4HANA applications. Google Cloud has invested significantly in tailoring its cloud offerings specifically for SAP applications and is rapidly gaining market share in this exponentially growing space. Ameri100 is at the forefront of assisting customers in implementing or migrating their SAP systems to the cloud and Google Cloud is our chosen hyperscale partner for these projects.

Ameri100 Announces Google Cloud Platform Webinar Series for SAP Customers

Eliminates All Adverse Warrants Eliminates All Adverse Warrants

AMERI Holdings Announces Warrant Exchange

Company to Host VIP Dinner with Prospective and Current Customers to Showcase Capabilities Company to Host VIP Dinner with Prospective and Current Customers to Showcase Capabilities

Ameri100 to Host HCM Cloud Solutions Events at SuccessConnect® 2019 in Las Vegas September 16-18

ATLANTA, Ga., Aug.  26, 2019  (GLOBE NEWSWIRE) -- AMERI Holdings, Inc. (NASDAQ: AMRH) (“Ameri100”), a specialized SAP® cloud, digital and enterprise solutions company, today announced that its Board of Directors, working together with its management team and legal and financial advisors, has commenced a process to explore, review, and evaluate a range of potential strategic alternatives focused on maximizing shareholder value. The Board of Directors has established a Special Committee comprised solely of independent directors to lead the strategic review process, and the Special Committee has retained independent legal advisors. The company has engaged a financial advisor to assist in its strategic review.

News for AMERI Hlds Stock (AMRH)